Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Amphastar Pharmaceuticals (AMPH) Other Gross PP&E Adjustments (2016 - 2025)

Amphastar Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 13 years, most recently at $568.6 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at $568.6 million for Q4 2025, up 9.99% from a year ago — trailing twelve months through Dec 2025 was $568.6 million (up 9.99% YoY), and the annual figure for FY2025 was $568.6 million, up 9.99%.
  • Other Gross PP&E Adjustments for Q4 2025 was $568.6 million at Amphastar Pharmaceuticals, down from $606.7 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for AMPH hit a ceiling of $606.7 million in Q3 2025 and a floor of $409.8 million in Q3 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was $485.2 million (2023), compared with a mean of $492.5 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: decreased 5.26% in 2022 and later rose 15.42% in 2025.
  • Amphastar Pharmaceuticals' Other Gross PP&E Adjustments stood at $438.6 million in 2021, then rose by 3.13% to $452.3 million in 2022, then increased by 15.4% to $522.0 million in 2023, then dropped by 0.97% to $517.0 million in 2024, then grew by 9.99% to $568.6 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were $568.6 million (Q4 2025), $606.7 million (Q3 2025), and $556.5 million (Q2 2025) per Business Quant data.